A generalised pustular psoriasis flare is one of the few genuine dermatological emergencies: widespread sterile pustulation with systemic inflammation, fever and a real risk of sepsis and death. Treatment has relied on retinoids, ciclosporin and methotrexate, none of which acts quickly.
This multicentre randomised double-blind placebo-controlled phase 2 trial in China enrolled 33 patients with moderate-to-severe acute flares and randomised them 2:1 to a single 1050 mg intravenous dose of recibokibart — a humanised IgG1 antibody against the interleukin-36 receptor — or placebo on day 1. Patients with persistent activity at day 8 could receive open-label drug.
The primary endpoint, a Generalised Pustular Psoriasis Physician Global Assessment pustulation sub-score of 0 or 1 at day 8, was met by 86.4% of the recibokibart group and 9.1% of placebo — a difference of 77.3 percentage points (95% CI 42.5 to 88.9, p<0.0001). A total GPPGA score of 0 or 1 was reached by 63.6% versus 0%, complete pustule clearance by 54.5% versus 0%, and mean GPPASI fell 59.3% versus no change. By week 4, 72.7% had achieved GPPASI 75. Improvement was visible within 24 hours.
Common adverse events were hypoproteinaemia, hypertriglyceridaemia, hyperlipidaemia and pruritus.
The interleukin-36 pathway is the correct mechanistic target — IL36RN mutations cause the familial form — and this is the second agent in that class to show this pattern of response. The caution is size: 33 patients, 22 on active drug, and everything after day 8 includes open-label treatment. This establishes the mechanism works fast, not the long-term place of the drug.
- Treat a generalised pustular psoriasis flare as an emergency requiring rapid systemic control, not a slow escalation
- Interleukin-36 receptor blockade produces pustule clearance within days rather than weeks
- Read the durability data cautiously — everything beyond day 8 included open-label treatment
- Watch metabolic parameters: hypoproteinaemia, hypertriglyceridaemia and hyperlipidaemia were the common adverse events
- Where an IL-36 agent is unavailable, the flare still needs urgent systemic therapy and supportive care for fluid and thermoregulatory loss
The statistics, in plain English
A between-group difference of 77.3 percentage points is enormous, but the confidence interval — 42.5 to 88.9 — is wide because there were only 33 patients. The lower bound still represents a large effect, so the direction is not in doubt; the precise magnitude is. The design detail that limits interpretation is the open-label rescue: patients with persistent disease at day 8 could receive active drug regardless of allocation, so any comparison after day 8 is no longer randomised and the week 4 and week 12 figures describe a treated cohort rather than a treatment effect. The day 8 primary endpoint is the only fully randomised comparison here.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free